Saad Usmani to Surveys and Questionnaires
This is a "connection" page, showing publications Saad Usmani has written about Surveys and Questionnaires.
Connection Strength
0.246
-
Hashmi H, Kumar A, Kharfan-Dabaja MA, Munshi PN, Inamoto Y, DeFilipp Z, Dholaria B, Jain T, Perales MA, Carpenter PA, Hamadani M, Dhakal B, Usmani SZ. ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2024 08; 30(8):750-759.
Score: 0.119
-
Usmani SZ, Mateos MV, Hungria V, Iida S, Bahlis NJ, Nahi H, Magen H, Cavo M, Hulin C, White D, De Stefano V, Fastenau J, Slavcev M, Heuck C, Qin X, Pei H, Masterson T, Lantz K, Gries KS. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results. J Cancer Res Clin Oncol. 2021 Feb; 147(2):619-631.
Score: 0.093
-
Malik MA, Dalvi AA, Derkach A, Mart?nez JA, Hydren JR, Merlo G, Aldana AM, Ahlstrom JM, Usmani SZ, Chimonas S, Ortiz R, Shah UA. Diagnosis Disclosure and Related Illness Experience in Patients With Multiple Myeloma and Precursor Plasma Cell Disorders. Clin Lymphoma Myeloma Leuk. 2026 Jun; 26(6):e793-e801.e4.
Score: 0.034